Date:
April 5, 2021
Issue #:
1621
Summary:
The once-monthly, subcutaneously injected calcitonin
gene-related peptide (CGRP) receptor antagonist
erenumab-aooe (Aimovig) was approved by the FDA
in 2018 for preventive treatment of migraine in adults.
Now the FDA has added a new warning to its labeling
about a risk of new-onset hypertension and worsening
of preexisting hypertension associated with use of the
drug. CGRP is a potent microvascular vasodilator;
blocking or deleting it has produced hypertensive
effects in animals.
gene-related peptide (CGRP) receptor antagonist
erenumab-aooe (Aimovig) was approved by the FDA
in 2018 for preventive treatment of migraine in adults.
Now the FDA has added a new warning to its labeling
about a risk of new-onset hypertension and worsening
of preexisting hypertension associated with use of the
drug. CGRP is a potent microvascular vasodilator;
blocking or deleting it has produced hypertensive
effects in animals.
